KalVista Pharmaceuticals (KALV) Non-Current Deffered Revenue (2014 - 2020)
KalVista Pharmaceuticals (KALV) reported Non-Current Deffered Revenue of $2.5 million for Q1 2020, down 31.81% on a YoY basis from $3.7 million in Q1 2019, and down 9.22% sequentially from $2.8 million in Q4 2019.
KalVista Pharmaceuticals (KALV) Non-Current Deffered Revenue (2014 - 2020) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 6 years of Non-Current Deffered Revenue data on file, last reported at $2.5 million in Q1 2020.
- For the quarter ending Q1 2020, Non-Current Deffered Revenue fell 31.81% year-over-year to $2.5 million; the trailing twelve-month figure through Jan 2020 stood at $2.5 million (down 31.81% YoY), and the FY2019 full-year result was $3.3 million, down 69.23% from the prior year.
- Non-Current Deffered Revenue eased to $2.5 million in Q1 2020, from $2.8 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $13.9 million in Q1 2018 to a low of $49000.0 in Q1 2016.
- A 4-year average of $5.3 million and a median of $3.5 million in 2019 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue soared 2350.0% in 2016 and plunged 73.61% in 2019, its largest moves.
- Tracing KALV's Non-Current Deffered Revenue over 4 years: stood at $49000.0 in 2016, then surged by 9430.61% to $4.7 million in 2018, then slumped by 41.03% to $2.8 million in 2019, then dropped by 9.22% to $2.5 million in 2020.
- Business Quant data shows KALV's Non-Current Deffered Revenue at $2.5 million in Q1 2020, $2.8 million in Q4 2019, and $2.9 million in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2020 | 2.50 Mn |
| Oct 31, 2019 | 2.75 Mn |
| Jul 31, 2019 | 2.87 Mn |
| Apr 30, 2019 | 3.34 Mn |
| Jan 31, 2019 | 3.67 Mn |
| Oct 31, 2018 | 4.67 Mn |
| Jul 31, 2018 | 8.47 Mn |
| Apr 30, 2018 | 10.86 Mn |
| Jan 31, 2018 | 13.89 Mn |
| Mar 31, 2016 | 49,000.00 |
| Dec 31, 2015 | 56,000.00 |
| Sep 30, 2015 | 64,000.00 |
| Jun 30, 2015 | 71,000.00 |
| Mar 31, 2015 | 2,000.00 |
| Dec 31, 2014 | 85,000.00 |